Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials.

IF 2.7 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Opinion on Emerging Drugs Pub Date : 2022-06-01 Epub Date: 2022-07-04 DOI:10.1080/14728214.2022.2094365

Xavier Thomas, Mohamed Elhamri, Alexandre Deloire, Maël Heiblig

{"title":"Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials.","authors":"Xavier Thomas, Mohamed Elhamri, Alexandre Deloire, Maël Heiblig","doi":"10.1080/14728214.2022.2094365","DOIUrl":null,"url":null,"abstract":"Introduction: Despite recent advances in the treatment of adult acute myeloid leukemia (AML), the clinical outcome of patients continues to be unsatisfactory especially among older patients, those with a high-risk profile, and in the relapsed/refractory setting. For this reason, recent clinical trials have explored novel therapeutic agents either used alone or in combination with intensive chemotherapy or low-intensity treatments.Areas covered: The current paper reviews the clinical development of monoclonal antibody-based therapies in AML, their current status and phases 2 and 3 prospective trials.Expert opinion: Monoclonal antibody-based therapies demonstrated efficacy and tolerability in several clinical trials, especially when used in combination either with '3 + 7' chemotherapy or with low-intensity treatments. Additional studies are needed to determine new antigens for antibody-based therapies that target leukemia stem cells and spare normal hematopoiesis. Phase 2 and 3 additional clinical trial data are needed to assess the promise of first trials, especially regarding chimeric antigen receptor T cells redirected against myeloid antigens and immune checkpoint inhibitor therapies.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"169-185"},"PeriodicalIF":2.7000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Emerging Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728214.2022.2094365","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 1

Abstract

Introduction: Despite recent advances in the treatment of adult acute myeloid leukemia (AML), the clinical outcome of patients continues to be unsatisfactory especially among older patients, those with a high-risk profile, and in the relapsed/refractory setting. For this reason, recent clinical trials have explored novel therapeutic agents either used alone or in combination with intensive chemotherapy or low-intensity treatments.

Areas covered: The current paper reviews the clinical development of monoclonal antibody-based therapies in AML, their current status and phases 2 and 3 prospective trials.

Expert opinion: Monoclonal antibody-based therapies demonstrated efficacy and tolerability in several clinical trials, especially when used in combination either with '3 + 7' chemotherapy or with low-intensity treatments. Additional studies are needed to determine new antigens for antibody-based therapies that target leukemia stem cells and spare normal hematopoiesis. Phase 2 and 3 additional clinical trial data are needed to assess the promise of first trials, especially regarding chimeric antigen receptor T cells redirected against myeloid antigens and immune checkpoint inhibitor therapies.

查看原文本刊更多论文

基于抗体的急性髓性白血病治疗:2期和3期试验回顾。

尽管最近在成人急性髓性白血病(AML)的治疗方面取得了进展，但患者的临床结果仍然不令人满意，特别是在老年患者、高风险患者和复发/难治性患者中。出于这个原因，最近的临床试验已经探索了新的治疗药物，无论是单独使用还是与强化化疗或低强度治疗联合使用。涵盖领域:本论文回顾了基于单克隆抗体的AML治疗的临床发展，它们的现状和2期和3期前瞻性试验。专家意见:在一些临床试验中，以单克隆抗体为基础的治疗显示出疗效和耐受性，特别是在与“3 + 7”化疗或低强度治疗联合使用时。需要进一步的研究来确定针对白血病干细胞和不影响正常造血的基于抗体的治疗的新抗原。需要额外的2期和3期临床试验数据来评估首次试验的前景，特别是关于靶向髓系抗原的嵌合抗原受体T细胞和免疫检查点抑制剂治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Emerging Drugs 医学-药学

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.